Breaking News
October 18, 2018 - Researchers to develop new stem cell-based strategies for treating vision disorders
October 18, 2018 - Detecting epigenetic signature may help people stay ahead of inflammatory bowel disease
October 18, 2018 - Understanding AFib: Slowing down the dancing heart
October 18, 2018 - Using NMR to Reduce Fraud
October 18, 2018 - New automated model identifies dense breast tissue in mammograms
October 18, 2018 - Mysterious polio-like illness baffles medical experts while frightening parents
October 18, 2018 - Cases of Acute Flaccid Myelitis on the rise across U.S.
October 18, 2018 - Dietary fiber reduces brain inflammation during aging
October 18, 2018 - New tool could help prioritize recovery efforts for the poorest hit by natural disasters
October 18, 2018 - Hundreds of dietary supplements shown to contain unapproved drugs
October 18, 2018 - Active Pharmaceuticals ID’d in >700 Dietary Supplements
October 18, 2018 - Cell death protein also damps inflammation
October 18, 2018 - Health Highlights: Oct. 15, 2018
October 18, 2018 - Largest study of ‘post-treatment controllers’ reveals clues about HIV remission
October 18, 2018 - Bad Blood in Silicon Valley: A conversation with John Carreyrou
October 18, 2018 - ANTRUK’s Annual Lecture sends out message on shortage of funds for antibiotic research
October 18, 2018 - NAM special publication outlines steps to ensure interoperability of health care systems
October 18, 2018 - Novel method uses just a drop of blood to monitor effect of lung cancer therapy
October 18, 2018 - New blood test could spare cancer patients from unnecessary chemotherapy
October 18, 2018 - Training young researchers to work with data volumes arising in the health sector
October 18, 2018 - New Metrohm IC method is reliable and convenient to use for zinc oxide assay
October 18, 2018 - Global AIDS, TB fight needs more money: health fund
October 18, 2018 - Understanding the forces that cause sports concussions
October 18, 2018 - Research points to new target for treating periodontitis
October 18, 2018 - New tool improves assessment of postpartum depression symptoms
October 18, 2018 - From Biopsy to Diagnosis
October 18, 2018 - Sexual harassment and assault linked to worse physical/mental health among midlife women
October 18, 2018 - Stumped by medical school? A Q&A with a learning specialist
October 18, 2018 - Self-lubricating condoms may help raise condom usage
October 18, 2018 - Targeting immune checkpoints in microglia could reduce out-of-control neuroinflammation
October 18, 2018 - Study finds changes in antiepileptic drug metabolism during different trimesters of pregnancy
October 18, 2018 - Autonomic nervous system directly controls stem cell proliferation, study shows
October 18, 2018 - FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
October 18, 2018 - Sleeping Beauty technique helps identify genes responsible for NAFLD-associated liver cancer
October 18, 2018 - Many U.S. adults confused about primary care, study shows
October 18, 2018 - UC researcher focuses on light-mediated therapies to target breast cancer
October 18, 2018 - With philanthropic gifts, Stanford poised to make major advances in neurosciences | News Center
October 18, 2018 - Mice study shows antibiotics are not always necessary to cure sepsis
October 18, 2018 - Researchers discover why heart contractions are weaker in individuals with HCM
October 18, 2018 - Participation in organized sport during childhood may have long-term skeletal benefits
October 18, 2018 - Probiotic/antibiotic combination could eradicate drug-resistant bacteria
October 17, 2018 - More Socioeconomic Challenges for Hispanic Women With HIV
October 17, 2018 - 49,XXXXY syndrome – Genetics Home Reference
October 17, 2018 - Scientists uncover possible new causes of Tourette syndrome
October 17, 2018 - Girl undergoes unusual heart surgery after compassionate-use exemption | News Center
October 17, 2018 - Health Issues That Are Sometimes Mistaken for Gluten Sensitivity
October 17, 2018 - Elective induction of labor at 39 weeks may be beneficial option for women and their babies
October 17, 2018 - New smart watch algorithms can accurately monitor wearers’ sleep patterns
October 17, 2018 - Researchers demonstrate epigenetic memory transmission via sperm
October 17, 2018 - FDA, DHS announce memorandum of agreement to address cybersecurity in medical devices
October 17, 2018 - Health Tip: Know the Risks of Chicken Pox
October 17, 2018 - Immunotherapy effective against hereditary melanoma
October 17, 2018 - Researchers reveal new mechanism for how animal cells stay intact | News Center
October 17, 2018 - Alzheimer's Goes Under the Cryo-Electron Microscope
October 17, 2018 - Medicare for all? CMS chief warns program has enough problems already
October 17, 2018 - Metrohm Raman introduces Mira P handheld Raman system
October 17, 2018 - Expanding the knowledge about hippocampus to better understand cognitive deficits in MS
October 17, 2018 - Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features
October 17, 2018 - Many healthy children may have metabolic risk factors, finds study
October 17, 2018 - A new antibiotic could be a better, faster treatment for tuberculosis
October 17, 2018 - “I will not become a Robot Doctor”: A medical student vows to practice compassion
October 17, 2018 - Study findings may explain sporadic outbreaks of C. difficile infections in hospitals
October 17, 2018 - Purdue researchers develop new chemical process to find better drug ‘fits’ for patients
October 17, 2018 - Yale researchers develop way to attack RNA with small-molecule drugs
October 17, 2018 - New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug
October 17, 2018 - Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
October 17, 2018 - Nine cases of polio-like illness suspected in children in illinois
October 17, 2018 - Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries
October 17, 2018 - Patients once thought incurable can benefit from high-dose radiation therapy
October 17, 2018 - Researchers awarded grant to advance testing of experimental heroin vaccine
October 17, 2018 - Researchers examine SSRI use during pregnancy and major gestational malformations
October 17, 2018 - FDA grants Rare Pediatric Disease Designation for Immusoft’s Iduronicrin genleukocel-T
October 17, 2018 - Reliable Respiratory announces acquisition of Attleboro Area Medical Equipment
October 17, 2018 - Study reveals link between childhood abuse and higher arthritis risk in adulthood
October 17, 2018 - Research shows people over 65 are not performing enough physical activity
October 17, 2018 - FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
October 17, 2018 - Weight gain after smoking cessation linked to increased short-term diabetes risk
October 17, 2018 - Researchers find opportunity to control salt-sensitive hypertension without exercising
October 17, 2018 - Women not warned about cancer associated with breast implants
October 17, 2018 - Metrohm offers robust handheld Raman analyzer for Defense and Security
Carnegie scientist awarded NIH grant to identify novel medicines for cardiovascular disease

Carnegie scientist awarded NIH grant to identify novel medicines for cardiovascular disease

image_pdfDownload PDFimage_print

Carnegie’s Department of Embryology scientist Steven Farber and team have been awarded a 5-year $3.3-million NIH grant to identify novel pharmaceuticals for combatting a host of diseases associated with altered levels of lipoproteins like LDL (“bad cholesterol”). Obesity, diabetes, cardiovascular disease, fatty liver disease, and metabolic syndrome have all been linked to changes in plasma lipoproteins.

Lab efforts, led by graduate student Jay Thierer, started by creating zebrafish that have been genetically engineered to produce glowing lipoproteins, a technique they call “LipoGlo”. This was achieved by attaching DNA encoding NanoLuc (a relative of the protein that makes fireflies glow) to Apolipoprotein-B (ApoB), the protein that carries bad cholesterol. Since all the types of lipoprotein particles that are thought to actually cause cardiovascular disease are made with one copy of the ApoB protein, the team just needs to quantify the amount of light coming from the fish and they know exactly how many disease causing particles there are. Finding compounds that lower ApoB levels could be an enormous boost to fighting cardiovascular disease.

To identify such compounds, Farber teamed up with Johns Hopkins Researchers Rexford Ahima, Thomas Lectka, and Jeffery Mumm and proposed a high-throughput screen that tests thousands of small molecules in live zebrafish larvae to identify those that lower ApoB. In addition, they developed a collection of secondary screens to help them figure out how a given compound achieves its ApoB-lowering effect.

What sets this research apart is its ability to study cardiovascular disease in the context of a living organism. Previous attempts to develop cardiovascular disease drugs have almost exclusively relied on studying a single cell type, such as finding ways to prevent liver cells from producing cholesterol. However, it is remarkably difficult to predict how changes in one cell type will affect the rest of the organism, as many tissues including muscle, fat, blood vessels, the liver, the intestine, and the brain all interact and communicate to regulate cholesterol.

What has made this effort possible are the unique attributes of the larval zebrafish system. Zebrafish have almost all of the major components of human metabolism, but in a small, rapidly developing organism that can be moved around and placed in tiny wells with robots. In a single week, the team can raise over 20,000 larvae and test hundreds of compounds, something that might take months or years in other vertebrate animal systems. Additionally, larvae are translucent which enables the team to monitor a host of other aspects of metabolic health such as fat accumulation and inflammation using other genetically engineered fish with “glowing” markers of biological processes. Mumm’s lab pioneered the zebrafish robotic platform for studies of eye biology and brought that expertise to the team. Lectka’s expertise in small molecule chemistry will assist in selecting the most promising compounds that could most easily be transformed into drugs for humans. These carefully selected candidate drugs will be handed off to the Ahima lab to test their efficacy in mouse models of obesity and cardiovascular disease.

Farber pointed out that “25% of the world’s population dies of cardiovascular disease. While statin drugs have had a major impact on reducing mortality, folks still die from cardiovascular disease.” He went on to explain that although ApoB has a well-known role in metabolic disease, this protein is “enormous,” making it nearly impossible to study using traditional molecular techniques. By embracing state-of-the-art genome engineering approaches, Farber and his team were able to overcome this issue and generate zebrafish with glowing lipoproteins.

Farber remarked: “While most of the field works in humans or mouse, my lab pioneered the use of zebrafish for studies of lipid metabolism. What we proposed is simply not possible in any other vertebrate model system. I will never forget the day Jay walked into my office and showed me images of larval zebrafish revealing the locations of all of the ApoB containing lipoproteins…just so cool.”

Source:

https://carnegiescience.edu/news/steven-farber-awarded-33-million-nih-grant-identify-new-pharmaceuticals-fight-cardiovascular

Tagged with:

About author

Related Articles